PMID- 21239777
OWN - NLM
STAT- MEDLINE
DCOM- 20110422
LR  - 20161021
IS  - 1520-4383 (Electronic)
IS  - 1520-4383 (Linking)
VI  - 2010
DP  - 2010
TI  - Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma.
PG  - 93-100
LID - 10.1182/asheducation-2010.1.93 [doi]
AB  - With improvements in therapy, increasing dose intensity, early recognition of 
      toxicity, and enhanced supportive care, current outcomes in patients with 
      classical Hodgkin's lymphoma (HL) may be superior to disease-free and overall 
      survival (OS) predicted by existing prognostic models, including the 
      International Prognostic Score (IPS). The addition of biologic markers to 
      recognized clinical prognostic factors, including those of the IPS, may to 
      improve patient risk stratification and guide therapy in the future. However, the 
      identification of these markers has been problematic due to the lack of large, 
      confirmatory prospective trials, reproducibility and feasibility of the assays, 
      and failure to improve upon already recognized clinical risk factors. One 
      biomarker in particular, CD68, present on tumor infiltrating macrophages and 
      detectable by immunohistochemical staining, is significantly associated with both 
      shortened progression-free and disease-specific survivals in patients with HL at 
      diagnosis and at relapse. In addition, less than 5% CD68+ cells correlates with a 
      100% disease-specific survival in patients with early-stage HL. CD68 represents 
      just one of the many prognostic markers that could eventually be used to 
      risk-stratify therapy. In addition, biologic markers may not only serve as 
      prognostic markers, but also as therapeutic targets in HL. This review examines 
      current data using the IPS to determine patient outcome, discuss several 
      potential biologic prognostic markers, and summarize new therapies that are 
      currently in clinical development in HL.
FAU - Blum, Kristie A
AU  - Blum KA
AD  - Division of Hematology, The Arthur G. James Comprehensive Cancer Center and The 
      Ohio State University, Columbus, OH 43210, USA. kristie.blum@osumc.edu
LA  - eng
GR  - K23 CA109004-01A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Hodgkin Disease/*diagnosis/*drug therapy
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - Prognosis
EDAT- 2011/01/18 06:00
MHDA- 2011/04/26 06:00
CRDT- 2011/01/18 06:00
PHST- 2011/01/18 06:00 [entrez]
PHST- 2011/01/18 06:00 [pubmed]
PHST- 2011/04/26 06:00 [medline]
AID - 2010/1/93 [pii]
AID - 10.1182/asheducation-2010.1.93 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2010;2010:93-100. doi: 
      10.1182/asheducation-2010.1.93.